Novartis AG (NVS)

86.91
0.23 0.27
NYSE : Health Technology
Prev Close 86.68
Open 86.61
Day Low/High 86.61 / 87.57
52 Wk Low/High 72.67 / 94.19
Volume 983.17K
Avg Volume 1.41M
Exchange NYSE
Shares Outstanding 2.63B
Market Cap 219.80B
EPS 3.30
P/E Ratio 26.43
Div & Yield 2.21 (2.72%)

Latest News

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.

Dow, S&P 500 and Nasdaq Finish Higher, Posting Third Consecutive Day of Gains

Dow, S&P 500 and Nasdaq Finish Higher, Posting Third Consecutive Day of Gains

Stocks ended higher on Tuesday.

IIROC Trading Halt - NVS

IIROC Trading Halt - NVS

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign

Chief executive David Hung resigned from the Basel, Switzerland, biotech after just 10 months on the job.

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

The Creating and Restoring Equal Access to Equivalent Samples Act, a measure aimed at making it easier for generic drug companies to research name brand drugs, was left out of the final budget.

There Is Good and a Lot of Bad in General Electric Earnings

There Is Good and a Lot of Bad in General Electric Earnings

John Flannery sees progress being made on GE's initiatives, but that is what I expected him to say.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

Why Thousands Will Attend ASH Hematology Conference in Atlanta This Weekend

Why Thousands Will Attend ASH Hematology Conference in Atlanta This Weekend

The FDA approved 11 different hematological treatments this year after approving 11 in the previous two years combined.

3 Things You Must Know About Wall Street as You Head to Lunch

3 Things You Must Know About Wall Street as You Head to Lunch

The Dow Jones Industrial Average soars on Monday, and the S&P 500 posts a sharp increase as the Senate passes its version of U.S. tax reform.

What Does CVS's Aetna Acquisition Mean for Amazon?

What Does CVS's Aetna Acquisition Mean for Amazon?

Is CVS's planned acquisition of Aetna just a reaction to Amazon's dive into healthcare? Here's what we know so far.

CVS Spends $69 Billion to Buy Aetna -- All Eyes Now on Amazon

CVS Spends $69 Billion to Buy Aetna -- All Eyes Now on Amazon

Insiders are already looking beyond the upcoming merger to the patron saint of disruption Amazon.

Amazon's Move Into Retail Pharmacy Could Put 10% of Industry Profits at Risk

Amazon's Move Into Retail Pharmacy Could Put 10% of Industry Profits at Risk

The likes of CVS and Walgreens could suffer if Amazon follows through on reported talks it's held with Mylan and Sandoz to get its feet wet in the prescription drug retail market.

Senate Tax Bill, Car Sales and Amazon - 5 Things You Must Know

Senate Tax Bill, Car Sales and Amazon - 5 Things You Must Know

U.S. stock futures are pointing to losses for Wall Street on Friday, after the Senate delays a vote on its tax reform bill over deficit concerns.

Novartis Reportedly Taps Centerview to Evaluate Options for Dermatology Business

Novartis Reportedly Taps Centerview to Evaluate Options for Dermatology Business

The Switzerland-headquartered drug manufacturer is reportedly mulling a sale of its dermatology generics drug unit, which is based primarily in the U.S.

GlaxoSmithKline Wins FDA Approval to Develop 'Breakthrough' Blood Cancer Drug

GlaxoSmithKline Wins FDA Approval to Develop 'Breakthrough' Blood Cancer Drug

The FDA cleared GSK's new drug for fast-track development with quicker regulatory review.

Drug Companies Respond to States Generic Drug Lawsuit

Drug Companies Respond to States Generic Drug Lawsuit

State attorneys general led by Connecticut's George Jepsen said Tuesday that were planning to include Mylan president Rajiv Malik and Emcure Pharmaceuticals Ltd. executive Satish Mehta in an expanded complaint in the federal generic drug antitrust lawsuit.

Starbucks Might Be About to Shock the Hell Out of Wall Street

Starbucks Might Be About to Shock the Hell Out of Wall Street

Starbucks used to be a can't miss investment. But this year the stock has languished for a variety of reasons. Wall Street could get a scary wake-up call.

Washington Uncertainty and a Healthcare Selloff Send Stocks Lower

Washington Uncertainty and a Healthcare Selloff Send Stocks Lower

Uncertainty in Washington, D.C., a healthcare sector in selloff mode and a big deals day on Wall Street sent U.S. equities lower to begin the week.

The Deal Market Still Looks Red-Hot

The Deal Market Still Looks Red-Hot

The European Central Bank may have lit a fourth quarter fire under Europe's M&A market.

Stocks Burrow Further Into the Red on Logistics of Tax Cut Plan

Stocks Burrow Further Into the Red on Logistics of Tax Cut Plan

Stocks dig further into the red on Monday, Oct. 30, as investors weigh how a proposed phase-in corporate tax rate cut might impact U.S. companies.

Merck Weighs on Dow but Apple and Tech Rally Give Lift to Nasdaq

Merck Weighs on Dow but Apple and Tech Rally Give Lift to Nasdaq

Stocks are mixed on Monday as Mueller's Russia investigation takes its first concrete steps.

Stock Futures Lower as Manafort Told to Surrender in Mueller Probe

Stock Futures Lower as Manafort Told to Surrender in Mueller Probe

Stock futures are lower on Monday as Mueller's Russia investigation takes its first concrete steps.

Novartis, Akzo Nobel and Axalta - 5 Things You Must Know Before the Market Opens

Novartis, Akzo Nobel and Axalta - 5 Things You Must Know Before the Market Opens

U.S. stock futures are lower on Monday.

Novartis To Buy Advanced Accelerator for $3.9 Billion in Oncology Push

Novartis To Buy Advanced Accelerator for $3.9 Billion in Oncology Push

Under the deal Novarits will make a cash offer of $41 a share for Nasdaq-listed AAA and $82 per American Depositary Share, subject to certain conditions, valuing AAA at $3.9 billion

Tech Bulls Can't Be Contained: Cramer's 'Mad Money' Recap (Friday 10/27/17)

Tech Bulls Can't Be Contained: Cramer's 'Mad Money' Recap (Friday 10/27/17)

Jim Cramer looks at Amazon, Alphabet, Intel and Microsoft and says his biggest problem in analyzing them is that they are such visionaries, he just can't keep up.

Baozun, J.M. Smucker Co., Southwest, Novartis: 'Mad Money' Lightning Round

Baozun, J.M. Smucker Co., Southwest, Novartis: 'Mad Money' Lightning Round

Jim Cramer is bullish on Baozun, Southwest Airlines Co., Union Pacific, CSX.

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Powerhouse performances from Caterpillar and 3M inspire a Dow rally, leading the index to new all-time highs in its 54th record close of the year.

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Better-than-expected earnings from a number of key Dow components sweep markets higher.

TheStreet Quant Rating: B- (Buy)